A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
一项针对接受 EGFR-TKI 治疗后出现渐进性、寡转移性或潜在进展的晚期非小细胞肺癌患者的 II 期试验,评估安罗替尼联合 EGFR-TKI 的疗效 (CTONG-1803/ALTER-L001)
期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-024-01656-0
Chen, Hua-Jun; Tu, Hai-Yan; Hu, Yanping; Fan, Yun; Wu, Guowu; Cang, Shundong; Yang, Yi; Yang, Nong; Ma, Rui; Jin, Gaowa; Xu, Ximing; Liu, Anwen; Tang, Shubin; Cheng, Ying; Yu, Yan; Xu, Chong-Rui; Zhou, Qing; Wu, Yi-Long